Konu "1st-Line Treatment" için PubMed İndeksli Yayın Koleksiyonu listeleme
Toplam kayıt 1, listelenen: 1-1
-
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
(Springer, 2022)Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...